Form D · Pharmaceuticals
Lennham Pharmaceuticals, Inc.
Concord, MA · CIK 0001853301
Offering snapshot reported Apr 4, 2023 · SEC filing
- Reported sold
- $1.2M Offering amount: $1.2M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Oct 28, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 4, 2023 | Initial | $1,200,000 | No comparison | 13 | SEC filing |
| Mar 25, 2021 | Initial | $2,325,000 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-477817
Offering and sales amounts consist of convertible note investments with an aggregate principal amount of $1,200,000.
Source: Form D, filed Apr 4, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Benjamin D. Enerson | Executive |
| Corey Mac Gregor | Executive |
| Bradford C. Sippy | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
53 Main Street Suite 206
Concord, MA, 01742
Concord, MA, 01742